title: OKT3 induction therapy: influence of duration on rejections and infections.
abstract: Anti-lymphocytes induction therapy in renal transplants remains controversial relative to efficacy and cost benefit. It has been suggested that shortening the duration of induction therapy from 14 to 7 d would provide adequate efficacy at less cost. Our objective was to compare the efficacy and complications of short (7 d or less, group A) versus standard (14 d or more, group B) duration of OKT3 induction therapy in renal allograft recipients. We performed a retrospective review of all renal allografts performed between July 1989 and September 1994. Two groups were identified based on the duration of OKT3 induction therapy. There were no significant differences between group A or B in the distribution of age, sex, race, degree of HLA matching, and etiology or renal failure. Patients in group B experienced fewer rejections at 3 and 12 months (p = 0.0236 and p = 0.0065, respectively) as well as fewer viral infections during the first year of follow-up (p = 0.0435). No difference on the mean number of bacterial or fungal infections existed between the two groups. There were no statistically significant differences in patient or graft survival, although patients in group B had a tendency towards increased 1-yr graft survival.
authors.affiliation: Department of Surgery, Louisiana State University Medical Center/Willis Knighton Regional Transplant Center, Shreveport 71130, USA.
authors.forename: G B
authors.initials: GB
authors.lastname: Zibari
authors.forename: K N
authors.initials: KN
authors.lastname: Boykin
authors.forename: J P
authors.initials: JP
authors.lastname: Thomas
authors.forename: D F
authors.initials: DF
authors.lastname: Aultman
authors.forename: S A
authors.initials: SA
authors.lastname: Aradhye
authors.forename: R W
authors.initials: RW
authors.lastname: McMillan
authors.forename: J C
authors.initials: JC
authors.lastname: McDonald
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D006084:Graft Rejection / Q000209:etiology / Q000628:therapy*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007239:Infections / Q000209:etiology / Q000628:therapy*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3